JAK inhibition in myelofibrosis

New England Journal of Medicine

Volumn 363, Issue 25, 2010, Pages 2464-

  Arellano Rodrigo, Eduardo ^a   Alvarez Larrán, Alberto ^b  

^a HOSPITAL CLÍNIC   (Spain)

^b HOSPITAL DEL MAR   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

HEMOGLOBIN; JANUS KINASE; JANUS KINASE 1; JANUS KINASE 2; JANUS KINASE INHIBITOR; THROMBOPOIETIN RECEPTOR;

ENZYME INHIBITION; HEMOGLOBIN BLOOD LEVEL; HUMAN; INCIDENCE; LETTER; MYELOFIBROSIS; PALLIATIVE THERAPY; PRIORITY JOURNAL; THROMBOSIS;

EID: 78650219911     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMc1011635     Document Type: Letter

References (6)

1. Verstovsek S, Kantarjian H, Mesa RA, et al. Safety and efficacy of INCB018424, a JAK1 and JAK2 inhibitor, in myelofibrosis. N Engl J Med 2010;363:1117-27.
2. Barbui T, Carobbio A, Cervantes F, et al. Thrombosis in primary myelofibrosis: incidence and risk factors. Blood 2010;115:778-82.
3. Moliterno AR, Hexner E, Roboz GJ, et al. An open-label study of CEP-701 in patients with JAK2 V617F-PV and ET: update of 39 enrolled patients. Blood 2009;114:753. abstract.
4. Guglielmelli P, Pancrazzi A, Bergamaschi G, et al. Anaemia characterises patients with myelofibrosis harbouring MPL mutation. Br J Haematol 2007;137:244-7.
5. Vannucchi AM. From palliation to targeted therapy in myelofibrosis. N Engl J Med 2010;363:1180-2.
6. Martínez-Trillos A, Gaya A, Maffioli M, et al. Efficacy and tolerability of hydroxyurea in the treatment of the hyperproliferative manifestations of myelofibrosis: results in 40 patients. Ann Hematol 2010;89:1233-7.